|
1
|
Bell D, Ranganathan S, Tao J and Monga SP:
Novel advances in understanding of molecular pathogenesis of
hepatoblastoma: A Wnt/β-catenin perspective. Gene Expr. 17:141–154.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liu S, Li N, Yu X, Xiao X, Cheng K, Hu J,
Wang J, Zhang D, Cheng S and Liu S: Expression of intercellular
adhesion molecule 1 by hepatocellular carcinoma stem cells and
circulating tumor cells. Gastroenterology. 144:1031–1041. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McGuire S: World Cancer Report 2014.
Geneva, Switzerland: World Health Organization, International
agency for research on cancer, WHO Press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stravitz RT, Heuman DM, Chand N, Sterling
RK, Shiffman ML, Luketic VA, Sanyal AJ, Habib A, Mihas AA, Giles
HC, et al: Surveillance for hepatocellular carcinoma in patients
with cirrhosis improves outcome. Am J Med. 121:119–126. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Martin WR, Eades CG, Thompson JA, Huppler
RE and Gilbert PE: The effects of morphine- and nalorphine-like
drugs in the nondependent and morphine-dependent chronic spinal
dog. J Pharmacol Exp Ther. 197:517–532. 1976.PubMed/NCBI
|
|
8
|
Walker JM, Bowen WD, Walker FO, Matsumoto
RR, de Costa B and Rice KC: Sigma receptors: Biology and function.
Pharm Rev. 42:355–402. 1990.PubMed/NCBI
|
|
9
|
Hanner M, Moebius FF, Flandorfer A, Knaus
HG, Striessnig J, Kempner E and Glossmann H: Purification,
molecular cloning, and the expression of the mammalian
sigma1-binding site. Proc Natl Acad Sci USA. 93:pp.
8072–8077. 1996; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aydar E, Palmer CP, Klyachko VA and
Jackson MB: The sigma receptor as a ligand-regulated auxiliary
potassium channel subunit. Neuron. 34:399–410. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hayashi T and Su TP: Sigma-1 receptor
chaperones at the ER-mitochondrion interface regulate
Ca2+ signaling and cell survival. Cell. 131:596–610.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Crawford KW and Bowen WD: Sigma-2 receptor
agonists activate a novel apoptotic pathway and potentiate
antineoplastic drugs in breast tumor cell lines. Cancer Res.
62:313–322. 2002.PubMed/NCBI
|
|
13
|
Brent PJ and Pang GT: Sigma binding site
ligands inhibit cell proliferation in mammary and colon carcinoma
cell lines and melanoma cells in culture. Eur J Pharmacol.
278:151–160. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hellewell SB, Bruce A, Feinstein G,
Orringer J, Williams W and Bowen WD: Rat liver and kidney contain
high densities of sigma 1 and sigma 2 receptors: Characterization
by ligand binding and photoaffinity labeling. Eur J Pharmacol.
268:9–18. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vilner BJ, John CS and Bowen WD: Sigma-1
and sigma-2 receptors are expressed in a wide variety of human and
rodent tumor cell lines. Cancer Res. 55:408–413. 1995.PubMed/NCBI
|
|
16
|
Aydar E, Palmer CP and Djamgoz MB: Sigma
receptors and cancer: Possible involvement of ion channels. Cancer
Res. 64:5029–5035. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolfe SA Jr, Culp SG and De Souza EB:
Sigma-receptors in endocrine organs: Identification,
characterization, and autoradiographic localization in rat
pituitary, adrenal, testis, and ovary. Endocrinology.
124:1160–1172. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xu QX, Li EM, Zhang YF, Liao LD, Xu XE, Wu
ZY, Shen JH and Xu LY: Overexpression of sigma1 receptor and its
positive associations with pathologic TNM classification in
esophageal squamous cell carcinoma. J Histochem Cytochem.
60:457–466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
20
|
Milner AE, Levens JM and Gregory CD: Flow
cytometric methods of analyzing apoptotic cells. Methods Mol Biol.
80:347–354. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fernald K and Kurokawa M: Evading
apoptosis in cancer. Trends Cell Biol. 23:620–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thomas GE, Szücs M, Mamone JY, Bem WT,
Rush MD, Johnson FE and Coscia CJ: Sigma and opioid receptors in
human brain tumors. Life Sci. 46:1279–1286. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bem WT, Thomas GE, Mamone JY, Homan SM,
Levy BK, Johnson FE and Coscia CJ: Overexpression of sigma
receptors in nonneural human tumors. Cancer Res. 51:6558–6562.
1991.PubMed/NCBI
|
|
24
|
Aydar E, Onganer P, Perrett R, Djamgoz MB
and Palmer CP: The expression and functional characterization of
sigma (sigma) 1 receptors in breast cancer cell lines. Cancer Lett.
242:245–257. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Crottès D, Guizouarn H, Martin P, Borgese
F and Soriani O: The sigma-1 receptor: A regulator of cancer cell
electrical plasticity? Front Physiol. 4:1752013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guitart X, Codony X and Monroy X: Sigma
receptors: Biology and therapeutic potential. Psychopharmacology.
174:301–319. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ruscher K, Shamloo M, Rickhag M, Ladunga
I, Soriano L, Gisselsson L, Toresson H, Ruslim-Litrus L, Oksenberg
D, Urfer R, et al: The sigma-1 receptor enhances brain plasticity
and functional recovery after experimental stroke. Brain.
134:732–746. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Spruce BA, Campbell LA, McTavish N, Cooper
MA, Appleyard MV, O'Neill M, Howie J, Samson J, Watt S, Murray K,
et al: Small molecule antagonists of the sigma-1 receptor cause
selective release of the death program in tumor and self-reliant
cells and inhibit tumor growth in vitro and in vivo. Cancer Res.
64:4875–4886. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Deng JY, Sun D, Liu XY, Pan Y and Liang H:
STAT-3 correlates with lymph node metastasis and cell survival in
gastric cancer. World J Gastroenterol. 16:5380–5387. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim HS, Park YH, Lee J, Ahn JS, Kim J,
Shim YM, Kim JH, Park K, Han J and Ahn MJ: Clinical impact of
phosphorylated signal transducer and activator of transcription 3,
epidermal growth factor receptor, p53, and vascular endothelial
growth factor receptor 1 expression in resected adenocarcinoma of
lung using tissue microarray. Cancer. 116:676–685. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kanda N, Seno H, Konda Y, Marusawa H,
Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y,
et al: STAT3 is constitutively activated and supports cell survival
in association with survivin expression in gastric cancer cells.
Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu WY, Li J, Wu ZS, Zhang CL, Meng XL and
Lobie PE: Prognostic significance of phosphorylated signal
transducer and activator of transcription 3 and suppressor of
cytokine signaling 3 expression in hepatocellular carcinoma. Exp
Ther Med. 2:647–653. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karin M: Nuclear factor-kappaB in cancer
development and progression. Nature. 441:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
|
